Fig. 4 | Scientific Reports

Fig. 4

From: Automated and closed clinical-grade manufacturing protocol produces potent NK cells against neuroblastoma cells and AML blasts

Fig. 4

CD69 expression in non-activated and activated NK Cells. NK cells were produced in the CliniMACS Prodigy and the expression was studied with flow cytometry from CD56 + NK cells, as part of the quality control panel. The fluorescence histograms for activated NK cells (end product), corresponding non-activated NK cells (after CD56-enrichment), and FMO control are shown.

Back to article page